TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03232177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagre Cap.
Description: from 0.5mg twice a day to maximally increase total10mg in 8 weeks and maintain maximal tolerable dose to 104 weeks
Study: NCT02991053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Study: NCT03958617

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bilateral Deep brain stimulation of the thalamus, Medtronic Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Deep brain stimulation of the thalamus, Medtronic Device
Study: NCT04297384

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive standard chemotherapy educational materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive personalized information about cancer, treatment, and side effects

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete surveys
Study: NCT02098473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPC4046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPC4046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05600257

Intervention type: DEVICE
Intervention: DBT
Description: Image with digital breast tomosynthesis

Intervention type: DEVICE
Intervention: DBT
Description: Image with digital breast tomosynthesis

Intervention type: DEVICE
Intervention: DM
Description: Image with digital mammography

Intervention type: DEVICE
Intervention: DM
Description: Image with digital mammography
Study: NCT00619398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506MR capsule
Description: Oral
Study: NCT02118246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling was performed for one week, three times a week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Kinesio tape was performed for one week, three times a week.
Study: NCT01485367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene gel 0.3%
Description: A pea size drop of Adapalene gel 0.3% will be applied to the odd numbered subjects on the left dorsal hand \& extensor forearm. A pea size drop of Adapalene gel 0.3% will be applied to the even numbered subjects on the right dorsal hand \& extensor forearm. The randomized area will be cleansed with Cetaphil Gentle Cleanser before applying the study medication. All subjects will apply sunscreen with zinc oxide in the morning to both the right \& left forearms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene gel 0.3%
Description: A pea size drop of Adapalene gel 0.3% will be applied to the odd numbered subjects on the left dorsal hand \& extensor forearm. A pea size drop of Adapalene gel 0.3% will be applied to the even numbered subjects on the right dorsal hand \& extensor forearm. The randomized area will be cleansed with Cetaphil Gentle Cleanser before applying the study medication. All subjects will apply sunscreen with zinc oxide in the morning to both the right \& left forearms.
Study: NCT04203771

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic AB-DENTALAC
Description: Orodispersible tablets containing Lactobacillus plantarum \[now Lactoplantibacillus plantarum\] KABP051 (CECT7481) and Lactobacillus brevis \[now Levilactobacillus brevis\] KABP052 (CECT7480) as active ingredients, at a minimum dose of 5x10\^8 cfu each, and sorbitol (E420) and guar gum (E412) as excipients, taken b.i.d. for 7 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orodispersible tablets made of sorbitol (E420) and guar gum (E412), taken b.i.d for 7 days.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgical removal of mandibular third molars at baseline
Description: Surgical removal of both mandibular third molars, performed under intravenous sedation and loco-regional anesthesia (Articaine Hydrochloride 4% with Epinephrine 1:100.000), after having undergone a professional oral cleaning.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical removal of mandibular third molars at baseline
Description: Surgical removal of both mandibular third molars, performed under intravenous sedation and loco-regional anesthesia (Articaine Hydrochloride 4% with Epinephrine 1:100.000), after having undergone a professional oral cleaning.
Study: NCT04297384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys
Study: NCT04723524

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Jinhua Qinggan (JHQG) Granules, Traditional Chinese Medicine
Description: Jinhua Qinggan granules: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Jinhua Qinggan granules simulation (placebo) agent: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
Study: NCT01840176

Intervention type: PROCEDURE
Group type: OTHER
Intervention: McCall culdoplasty
Description: The modified McCall Culdoplasty procedure is a relatively simple procedure that is performed after removal of the uterus and cervix from the apex of the vagina wherein the angles of the vagina are attached to their respective uterosacral ligament and the cul-de-sac is surgically obliterated for support postoperatively. This is done with a single 0-vicryl suture. There will be no additional interventions applied during the hysterectomy aside from the McCall culdoplasty.
Study: NCT00003207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSC 833
Study: NCT04284007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone with perineural levobupivacaine
Description: Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 4 mg intravenous dexamethasone diluted in 10 ml saline.
Study: NCT04167761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Adipose tissue samples collected from participants were treated with Ertugliflozin at a concentration of 25 µM in vitro. This treatment was applied in a laboratory setting to assess the effects of Ertugliflozin on lipolysis, inflammatory cytokine release, and gene expression in epicardial, pericardial, and subcutaneous adipose tissue
Study: NCT04203771

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen syrup at 20-30 mg/Kg of body weight, orally every 8 hours (t.i.d), for 7 days
Study: NCT02007083

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral laminotomy (BL)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral laminotomy with crossover (UL)
Study: NCT04203771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen syrup at 20-30 mg/Kg of body weight, orally every 8 hours (t.i.d), for 7 days
Study: NCT02007083

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinous Process Osteotomy (SPO)
Study: NCT03949387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES Cycling Exercise
Description: FES cycling will use self-adhering surface electrodes (Pals Platinum, Fallbrook, CA) placed over the quadriceps, hamstrings, and gluteal muscle groups to deliver stimulation to the leg muscles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Passive Leg Cycling
Description: Passive leg cycling will not involve electrical stimulation
Study: NCT01257217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1
Description: Multifocal IOL implanted for long-term use over the lifetime of the cataract patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT
Description: Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acri.LISA® 366D IOL
Description: Aspheric diffractive IOL with +3.75 D add power implanted for long-term use over the lifetime of the cataract patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acri.LISA® 466TD Toric IOL
Description: Aspheric diffractive IOL with +3.75 D add power and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
Study: NCT05316636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrational forces

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrational forces
Study: NCT02300077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone
Description: Escalating dose of methadone up to .3mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone
Description: Escalating dose of methadone up to .3mg/kg.
Study: NCT05316636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with clear aligners

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with clear aligners
Study: NCT03907579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inflatable colon educational module
Description: Participants attend a brief educational presentation in an inflatable colon, learning about colorectal cancer prevention and screening.
Study: NCT02300077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control (Intra-operative administration of opioids, other than methadone)
Description: Intra-operative administration of opioids, other than methadone
Study: NCT02991950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parnaparin Sodium
Description: Parnaparin sodium ( Fluxum 4250 anti-Xa IU /0.4 mL or Fluxum 6400 anti-Xa IU /0.6mL; Alfa Wassermann S.p.A.) was administered at a dose of 100 IU/kg/day from the day before the beginning of the stimulation phase of the cycle until the result of the procedure was confirmed by pregnancy and, in the case of evolutive pregnancy, until delivery or the end of pregnancy
Study: NCT05316636

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic treatment with clear aligners
Study: NCT03407222

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text messages
Description: Text messages which encourage the increment of daily step count
Study: NCT03800901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuing Medical Education
Description: CME or ABIM MOC credits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality IQ Patient Simulations
Description: Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, including national MIPS quality measures.~Cases will cover clinical conditions aligned with MIPS measures that are commonly seen in the primary care setting including: diabetes, hypertension, depression, osteoarthritis, asthma and pain control.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality IQ Patient Simulations
Description: Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, including national MIPS quality measures.~Cases will cover clinical conditions aligned with MIPS measures that are commonly seen in the primary care setting including: diabetes, hypertension, depression, osteoarthritis, asthma and pain control.
Study: NCT01158534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa-2b
Description: Given subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study: NCT01817946

Intervention type: OTHER
Intervention: Genetic Testing
Description: Genetic testing services will be provided by the University of Chicago under the guidance of Dr. Soma Das, PhD. Services will be coordinated by Rachel Alvarez, CMDIR Associate Director. Genetic testing will include standard sequencing of the MTM1 gene followed by CGH array for deletion/duplication in cases where no pathologic variant is identified by standard sequencing.
Study: NCT04526457

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Randomized to standard of care with lipid testing only.

Intervention type: OTHER
Group type: OTHER
Intervention: Genetic Testing
Description: Randomized to genetic testing.
Study: NCT03564067

Intervention type: DEVICE
Group type: OTHER
Intervention: Soterix Medical tDCS mini-Clinical Trials system (mini-CT)
Description: Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). Home-based tDCS will involve 30-min tDCS (3 days per week) for the first 3 months and once weekly for the subsequent 3 months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computerized CBT (cCBT)
Description: Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
Study: NCT03509480

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Curettage for benign bone lesion
Description: Surgical curettage for benign bone lesion, created defects will be filled with one of two types of graft material Vitoss versus Prodense, there are no other devices or drugs used

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Curettage for benign bone lesion
Description: Surgical curettage for benign bone lesion, created defects will be filled with one of two types of graft material Vitoss versus Prodense, there are no other devices or drugs used
Study: NCT03847818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib+Trastuzumab+Docetaxel+Carboplatin
Description: Drug: Pyrotinib Pyrotinib: 400mg orally daily~Drug: Trastuzumab Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;~Drug: Docetaxel Docetaxel: 75mg/m2 for a total of 6 cycles~Drug: Carboplatin Carboplatin: AUC=5 or 6 for a total of 6 cycles
Study: NCT00701740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral isotretinoin and Mexoryl SX / XL
Description: 20mg, 3/week,continuously for three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexoryl XL / SX
Description: 11 subjects used only the same moisturizer and SPF 60 sunscreen
Study: NCT02731040

Intervention type: DRUG
Intervention: Bisphosphonate

Intervention type: DRUG
Intervention: Bisphosphonate
Study: NCT02457351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roniciclib (BAY 1000394)
Description: Part 1 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 mg Cycle 1 Day 6: Single dose 2.5 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 or 5 mg (based on Part 1 data) Cycle 1 Day 6: Single dose 2.5 or 5 mg (based on part 1 data)~Part 1 \& Part 2~Cycle 2 and subsequent 21-day cycles:~Day 1-3 of each cycle: 5 mg bid Day 4-7 of each cycle: no dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole (Sporanox)
Description: Part 1 \& Part 2 of Cycle 1 Cycle 1 Day 4: 200 mg bid Cycle 1 Day 5-11: 200 mg qd
Study: NCT04201769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant/Palonosetron
Description: NEPA is adiministered 60 minutes before chemotherapy, on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant/Palonosetron
Description: NEPA is adiministered 60 minutes before chemotherapy, on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netupitant/Palonosetron
Description: NEPA is adiministered 60 minutes before chemotherapy, on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous dexamethasone 12 mg is administered 30 minutes before chemotherapy initiation, on day 1.~The administration of DEX in the subsequent days (2-4) depends on the randomly assignement to treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous dexamethasone 12 mg is administered 30 minutes before chemotherapy initiation, on day 1.~The administration of DEX in the subsequent days (2-4) depends on the randomly assignement to treatment arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous dexamethasone 12 mg is administered 30 minutes before chemotherapy initiation, on day 1.~The administration of DEX in the subsequent days (2-4) depends on the randomly assignement to treatment arm
Study: NCT02286115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life-Stress Interview
Description: A life-stress interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms, b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations
Study: NCT03955107

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitoring System
Description: Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) every 4 weeks since diagnosed with GDM，and the control grouponly once receive CGMS during the last month and have management adjusted based on the CGMS readings Other Name: iPro, Medtronic
Study: NCT03677089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12 ECHO Autism telehealth clinics
Description: Twice-monthly 2-hour ECHO Autism Clinics will be provided during a 6-month period. Each Clinic will include a didactic presentation, 2 to 3 Primary Care Provider-generated case presentations, expert feedback, and group discussion. Although the ECHO Clinic will include discussion of specific cases, no identifiable personal health information will be shared, individual patients will not be identified, and no direct patient care will be provided.
Study: NCT00069082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Civamide (Zucapsaicin)
Description: Nasal Solution 0.01%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Nasal Solution 10%
Study: NCT02433210

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELISIO-15H
Description: Each patient to undergo 3 successive hemodialysis/week with this dialyzer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELISIO-15H
Description: Each patient to undergo 3 successive hemodialysis/week with this dialyzer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELISIO-15H
Description: Each patient to undergo 3 successive hemodialysis/week with this dialyzer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Revaclear
Description: Each patient to undergo 3 successive hemodialysis/week with this dialyzer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Revaclear
Description: Each patient to undergo 3 successive hemodialysis/week with this dialyzer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Revaclear
Description: Each patient to undergo 3 successive hemodialysis/week with this dialyzer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optiflux
Description: Each patient to undergo 3 successive hemodialysis/week with this dialyzer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optiflux
Description: Each patient to undergo 3 successive hemodialysis/week with this dialyzer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optiflux
Description: Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
Study: NCT03135028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: 400 mg (2 × 200 mg tablets) orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: 400 mg (2 × 200 mg tablets) orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: 60 mg/m\^2 administered intravenously daily on Days 1 to 3 of each 28-day induction cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m\^2 intravenous administration twice daily on Days 1 to 7 of each 28-day induction cycle~Hi-DAC: 3 g/m\^2 IV administration twice daily on days 1, 3, and 5 (≤ 60 years of age) or 1 g/m\^2 IV administration once daily on Days 1 to 5 (\> 60 years of age) of each 28-day post-remission cycle
Study: NCT02521051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT03481517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine 5 mL subcutaneous injection to surgical wound during operation.